6. Anti-infective medicines

6.2. Antibacterials

6.2.1. Access group antibiotics

**Metronidazole**

**INN**
Metronidazole

**Medicine type**
Chemical agent

**Antibiotic groups**
ACCESS

**List type**
Core

**Formulations**
- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Local > Rectal > Suppository: 1 g suppository (EML) ; 500 mg suppository (EML)
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
- Oral > Solid > tablet: 200 mg ; 250 mg ; 400 mg ; 500 mg

**EML status history**
- First added in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions
- Read more about patents.

**Wikipedia**
Metronidazole

**DrugBank**
Metronidazole

---

**Expert Committee recommendation**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:
- the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc.
- replacing the oral liquid formulation of clindamycin (oral liquid 75 mg/5 mL) with powder for oral liquid 75 mg/5 mL (as palmitate hydrochloride) on the EML and EMLc.
- the addition of new strength formulations of IV vancomycin (500 mg; 1 g (as hydrochloride)) on the EMLc.

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended that the range of strengths of metronidazole tablets be replaced with reference to specific strengths on the EML and EMLc.

---

**EML recommendations: Necrotising fasciitis**

**First choice**

**Second choice**
metronidazole
co-prescribed with *ceftriaxone*

clindamycin
co-prescribed with *piperacillin + tazobactam*

vancomycin